BM-MSCs were the most prevalent source employed for assessments in lung disorders. In addition, because of their lower tumorigenicity, immunogenicity, and easier management, EVs, especially exosomes, may be a safer and efective therapeutic tools for treatment of lung conditions as compared with their parental MSCs. Nevertheless, the underlying mechanism in MSC-EVs biogenesis, pharmacokinetics and biodistribution requires very extensive investigates prior to the application of this approach in clinic. Further comprehensive experiments are also required to clarify the optimal protocol for isolation and preparation of MSCs for clinical use. Furthermore, modifcation or engineering of MSC-derived EVs can make them emerging therapeutic candidates for decreasing undesired adverse events in the future clinical use of MSC‐EVs.